Generalized anxiety disorder
For patient information click here
Template:DiseaseDisorder infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Synonyms and keywords: GAD; anxiety
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Overview
Generalized anxiety disorder (GAD) is an anxiety disorder that is characterized by excessive, uncontrollable and often irrational worry about everyday things, which is disproportionate to the actual source of worry. This excessive worry often interferes with daily functioning, as individuals suffering from GAD typically catastrophize, anticipate disaster, and are overly concerned about everyday matters such as health issues, money, family problems, or work difficulties.[1] They often exhibit a variety of physical symptoms, including fatigue, headaches, muscle tension, muscle aches, difficulty swallowing, trembling, twitching, irritability, sweating, and hot flashes. These symptoms must be consistent and on-going, persisting at least 6 months, for a formal diagnosis of GAD to be introduced. [1] Approximately 6.8 million American adults experience GAD, affecting about twice as many women as men.[2]
Historical Perspective
Generalized anxiety disorder was first recognized as a symptom by Sigmund Freud. In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.
Classification
Generalized anxiety disorder falls under the category of anxiety disorder.[3]
Pathophysiology
Generalized anxiety disorder has been linked to the disrupted functional connectivity of the amygdala and its processing of fear and anxiety.[4]
Differentiating Generalized anxiety disorder from other Disorders
The differential diagnosis in generalized anxiety disorder is similar to that of panic disorder. It is important to rule out drug-induced conditions. The mental status examination should take in consideration the possibility of schizophrenia, obsessive-compulsive disorder, major depressive disorder, and both specific and social phobias.
Epidemiology and Demographics
Generalized anxiety disorder is relatively common and has a lifetime prevalence of about 4-7% in the general population. It is more common in women, and can develop in any age although it more commonly occurs in the third and fourth decade of life. Approximately one quarter of the patients with generalized anxiety disorder, will develop panic disorder.
Risk Factors
Risk factors for developing generalized anxiety disorder include family history, early adulthood, and a recent life stressor.
History and Symptoms
The criteria for generalized anxiety disorder include at least 6 months of excessive anxiety or worry, about a number of situations, which is difficult to control. The worry may also be associated with three of the following symptoms; restlessness. fatigue, irritability, muscle tension, poor sleep, and difficulty concentrating. There are several disorders that have a tendency to co-occur with generalized anxiety disorder. These include; major depressive disorder, panic disorder, social phobia, agoraphobia, substance abuse, irritable bowel syndrome and sleep disorders.
Natural history, Complications, and Prognosis
In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%, and with panic disorder, 9.9%.
Diagnostic Criteria
The criteria for generalized anxiety disorder include at least 6 months of excessive anxiety or worry, about a number of situations, which is difficult to control. The worry may also be associated with three of the following symptoms; restlessness. fatigue, irritability, muscle tension, poor sleep, and difficulty concentrating.
History and Symptoms
There are several disorders that have a tendency to co-occur with generalized anxiety disorder. These include; major depressive disorder, panic disorder, social phobia, agoraphobia, substance abuse, irritable bowel syndrome and sleep disorders.
Laboratory Findings
There are no laboratory findings associated with generalized anxiety disorder.
Other Imaging Findings
There are no other imaging findings associated with generalized anxiety disorder.
Other Diagnostic Studies
There are no other diagnostic studies associated with generalized anxiety disorder.
Medical Therapy
There are a variety of medications which can be used to treat generalized anxiety disorder, and they generally work well particularly in conjunction with psychotherapy. The first line treatments are the SSRI class of antidepressants such as fluoxetine, paroxetine, and escitalopram. Other antidepressants such as imipramine, venlafaxine, and buspirone may also be effective. Benzodiazepines provide quick, effective relief from anxiety, however must be prescribed with caution due to a high risk of abuse and dependence.
Psychotherapy
A psychological method of treatment for GAD is cognitive behavioral therapy (CBT), which involves a therapist working with the patient to understand how thoughts and feelings influence behavior.[5] The goal of the therapy is to change negative thought patterns that lead to the patient’s anxiety, replacing them with positive, more realistic ones. Elements of the therapy include exposure strategies to allow the patient to gradually confront their anxieties and feel more comfortable in anxiety-provoking situations, as well as to practice the skills they have learned. CBT can be used alone or in conjunction with medication.
Neuroscience education may reduce catastrophizing among patients with chronic musculoskeletal pain[6].
Brain Stimulation Therapy
There is no FDA approved brain stimulation therapy available for generalized anxiety disorder.
References
- ↑ 1.0 1.1 “Anxiety Disorders”, National Institute of Mental Health. Accessed 28 May 2008.
- ↑ “The Numbers Count”, National Institute of Mental Health. Accessed 28 May 2007.
- ↑ Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
- ↑ Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009). “Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder”. Arch Gen Psychiatry. 66 (12): 1361–72. doi:10.1001/archgenpsychiatry.2009.104. PMID 19996041.
- ↑ “A Guide to Understanding Cognitive and Behavioural Psychotherapies”, British Association of Behavioural and Cognitive Psychotherapies. Accessed 29 May 2007.
- ↑ Siddall B, Ram A, Jones MD, Booth J, Perriman D, Summers SJ (2022). “Short-term impact of combining pain neuroscience education with exercise for chronic musculoskeletal pain: a systematic review and meta-analysis”. Pain. 163 (1): e20–e30. doi:10.1097/j.pain.0000000000002308. PMID 33863860 Check
|pmid=value (help).
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Overview
Generalized anxiety disorder was first recognized as a symptom by Sigmund Freud. In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.
Historical Perspective
- In the late 19th century, Sigmund Freud recognized anxiety as:[1]
- A “signal of danger”
- A cause of “defensive behavior“
- He believed we acquire anxious feelings through classical conditioning and traumatic experiences.
- In the 19th century into the 20th century, the terms used to diagnose generalized anxiety included:[2]
- “Pantophobia”
- “Anxiety neurosis”
- Such terms designated paroxysmal manifestations (panic attacks) as well as interparoxysmal phenomenology (the apprehensive mental state).
- Generalized anxiety was considered one of the numerous symptoms of neurasthenia, a vaguely defined illness.
- In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.
- Anxiety neurosis was split into:[3]
- GAD
- Panic disorder
- We maintain anxiety through operant conditioning;
- When we see or encounter something associated with a previous traumatic experience, anxious feelings resurface.
- We feel temporarily relieved when we avoid situations which make us anxious.
- Anxiety neurosis was split into:[3]
Development of Diagnostic Criteria for Generalized Anxiety Disorder
- In 1980, DSM-III portrayed GAD as:[4]
- Generalized, persistent anxiety
- In 1987, DMS-III-R portrayed GAD as:
- Unrealistic/excessive anxiety and worry (apprehensive expectation) about 2 or more life circumstances
- In 1992, ICD-10 portrayed GAD as:
- Generalized and persistent anxiety, not restricted to or even predominating in any environmental circumstances (ie, “free-floating”)
- The ICD-11, beta draft, portrayed GAD as:
- Marked symptoms of anxiety accompanied by either general apprehension (ie, “free-floating anxiety”) or worry focused on multiple everyday events (family, health, finances, school, or work)
- In 1994, DSM-IV portrayed GAD as:
- Excessive anxiety and worry (apprehensive expectation) about a number of events or activities
- Difficult to control the worry
- In 2013, DSM-V portrayed GAD as:
- Excessive anxiety and worry (apprehensive expectation) about a number of events or activities
- Difficult to control the worry
References
- ↑ Kessler RC, Keller MB, Wittchen HU (2001). “The epidemiology of generalized anxiety disorder”. Psychiatr Clin North Am. 24 (1): 19–39. PMID 11225507.
- ↑ Crocq MA (2017). “The history of generalized anxiety disorder as a diagnostic category”. Dialogues Clin Neurosci. 19 (2): 107–116. PMC 5573555. PMID 28867935.
- ↑ Torpy JM, Burke AE, Golub RM (2011). “JAMA patient page. Generalized anxiety disorder”. JAMA. 305 (5): 522. doi:10.1001/jama.305.5.522. PMID 21285432.
- ↑ Wittchen HU, Kessler RC, Zhao S, Abelson J (1995). “Reliability and clinical validity of UM-CIDI DSM-III-R generalized anxiety disorder”. J Psychiatr Res. 29 (2): 95–110. PMID 7666382.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Overview
Generalized anxiety disorder falls under the category of anxiety disorder.
Classification
- Generalized anxiety disorder falls under the category of anxiety disorder.[1]
References
- ↑ Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Irfan Dotani
Overview
Generalized anxiety disorder has been linked to the disrupted functional connectivity of the amygdala and its processing of fear and anxiety. Sensory information enters the amygdala through the nuclei of the basolateral complex (consisting of lateral, basal and accessory basal nuclei).
Pathophysiology
- Generalized anxiety disorder has been linked to the disrupted functional connectivity of the amygdala and its processing of fear and anxiety.[1]
- Sensory information enters the amygdala through the nuclei of the basolateral complex (consisting of lateral, basal and accessory basal nuclei). The basolateral complex processes the sensory-related fear memories and communicates their threat importance to elsewhere in the brain, such as the medial prefrontal cortex and sensory cortices, along with:[2]
- Another area, the adjacent central nucleus of the amygdala, controls species-specific fear responses in its connections to the brainstem, hypothalamus and cerebellum areas.
- In those with generalized anxiety disorder, these connections seem less functionally distinct, and there is greater gray matter in the central nucleus.
- Another difference is that the amygdala areas have decreased connectivity with the insula and cingulate areas that control general stimulus salience while having greater connectivity with the parietal cortex and prefrontal cortex circuits that underlie executive functions.[3]
References
- ↑ Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009). “Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder”. Arch Gen Psychiatry. 66 (12): 1361–72. doi:10.1001/archgenpsychiatry.2009.104. PMID 19996041.
- ↑ Kessler RC, Keller MB, Wittchen HU (2001). “The epidemiology of generalized anxiety disorder”. Psychiatr Clin North Am. 24 (1): 19–39. PMID 11225507.
- ↑ Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2012). “An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder”. World J Biol Psychiatry. 13 (7): 510–6. doi:10.3109/15622975.2011.624548. PMID 22059936.
- ↑ Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB; et al. (2005). “Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions”. Psychol Med. 35 (12): 1747–59. doi:10.1017/S0033291705006069. PMID 16202187.
Differentiating Generalized Anxiety Disorder from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2] Irfan Dotani
Overview
The differential diagnosis in generalized anxiety disorder is similar to that of panic disorder. It is important to rule out drug-induced conditions. The mental status examination should take in consideration the possibility of schizophrenia, obsessive-compulsive disorder, major depressive disorder, and both specific and social phobias.
Differential Diagnosis
- Adjustment disorder[1]
- Anxiety disorder due to another medical condition[1]
- Bipolar disorder[1]
- Panic disorder– anxiety is only in regards to having a panic attack
- Post-traumatic stress disorder– presence of flashbacks, hyper-arousal, and hyper-vigilance
- Social phobia– anxiety only occurs in regards to social situations
- Obsessive-compulsive disorder– presence of obsessions and compulsions[2]
- Separation anxiety disorder– anxiety occurs in response to being away from home or family
- Anorexia nervosa– anxiety occurs in response to potentially gaining weight
- Somatization disorder– multiple physical complaints
- Hypochondriasis– anxiety in regards to developing a specific disease
- Schizophrenia– presence of psychotic symptoms such as hallucinations and delusions
- Major depressive disorder– criteria requires two weeks of specific symptoms
- Medications– in particular stimulants such as methylphenidate, pseudoephedrine, and other decongestants or appetite suppressants
- Drug abuse– particularly stimulants and hallucinogenics such as cocaine, caffeine, amphetamines, and PCP[3]
- Drug withdrawal– particularly alcohol withdrawal, benzodiazepine withdrawal, and opiate withdrawal.
- Hyperthyroidism– presence of an elevated TSH on laboratory findings
Differentiating generalized anxiety disorder from other diseases
| Disease | Prominent clinical features | Investigations |
|---|---|---|
| Hyperthyroidism | The main symptoms include:[4]
|
|
| Essential hypertension | Most patients with hypertension are asymptomatic at the time of diagnosis. Common symptoms are listed below:[5] | JNC 7 recommends the following routine laboratory tests before initiation of therapy for hypertension:
|
| Generalized anxiety disorder | According to DSM V, the following criteria should be present to fit the diagnosis of generalized anxiety disorder:
|
– |
| Menopause | The perimenopausal symptoms are caused by an overall drop, as well as dramatic but erratic fluctuations, in the levels of estrogens, progestin, and testosterone. Some of these symptoms such as formication etc may be associated with the hormone withdrawal process.
|
|
| Opioid withdrawal disorder | According to DSM V, the following criteria should be present to fit the diagnosis of opioid withdrawal:[6]
|
|
| Pheochromocytoma | The hallmark symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity, symptoms usually subside in less than one hour and they may include:
Please note that not all patients with pheochromocytoma experience all classical symptoms. |
Diagnostic lab findings associated with pheochromocytoma include:
|
| Social phobia | The main symptoms include: |
|
| OCD | The main symptoms include:
|
|
| PTSD | The main symptoms include:
|
|
| Somatoform disorders | The main symptoms include:
|
|
| Depression | The main symptoms include:
|
|
| Substance-or drug-induced anxiety disorder | The main symptoms include:
|
|
| CNS-depressant withdrawal | The main symptoms include:
|
|
| Anorexia nervosa | The main symptoms include:
|
|
References
- ↑ 1.0 1.1 1.2 Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
- ↑ Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM; et al. (2007). “Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years”. Arch Gen Psychiatry. 64 (6): 651–60. doi:10.1001/archpsyc.64.6.651. PMID 17548747.
- ↑ Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG (2010). “Anxiety disorders in older adults: a comprehensive review”. Depress Anxiety. 27 (2): 190–211. doi:10.1002/da.20653. PMID 20099273.
- ↑ Smith JP, Book SW (2010). “Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment”. Addict Behav. 35 (1): 42–5. doi:10.1016/j.addbeh.2009.07.002. PMC 2763929. PMID 19733441.
- ↑ Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). “Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication”. Arch Gen Psychiatry. 62 (6): 617–27. doi:10.1001/archpsyc.62.6.617. PMC 2847357. PMID 15939839. Review in: Evid Based Ment Health. 2006 Feb;9(1):27
- ↑ Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2] Irfan Dotani
Overview
Generalized anxiety disorder is relatively common and has a lifetime prevalence of 900 per 100,000 (0.9%) in adolescents and 2,900 per 100,000 (2.9%) in adults.[1] It is more common in women, and can develop in any age although it more commonly occurs in the third and fourth decade of life.
Epidemiology and Demographics
Prevalence
- The 12-months prevalence in overall population is:
- 900 per 100,000 (0.9%) in adolescents
- 2,900 per 100,000 (2.9%) in adults[1]
- The World Health Organization‘s Global Burden of Disease project did not include generalized anxiety disorders.[2] In lieu of global statistics, here are some prevalence rates from around the world:
Age
- The disorder most commonly has its onset in the third decade of life, and mostly occurs in persons under the age of 30 years old. Generalized anxiety disorder can be seen at any age.
Gender
- Generalized anxiety disorder is more commonly seen in females. This may partly be due to the increased tendency of women to report symptoms.
Race
- Generalized anxiety disorder is more common in African Americans.
References
- ↑ 1.0 1.1 Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
- ↑ 2.0 2.1 “Relating the burden of anxiety and depression to effectiveness of treatment”, World Health Organization.
- ↑ http://www.canmat.org/resources/depression/gad.html
- ↑ 4.0 4.1 http://www.emedicine.com/med/byname/anxiety-disorders.htm
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Overview
Risk factors for developing generalized anxiety disorder include a positive family history, early adulthood, and a recent life stressor. Genetics along with substance-induced anxiety are large factors as well.
Risk Factors
Risk factors for generalized anxiety disorder include:[1]
- Behavioral inhibition
- Childhood adversities
- Genetic predisposition
- Harm avoidance
- Negative affectivity (neuroticism)
- Parental over-protection
Genetics
- Genes are attributed to about 33% of general anxiety disorder’s variance.[2]
- Individuals with a genetic predisposition for GAD are more likely to develop GAD.
- Especially in response to a life stressor.[3]
Substance-Induced
- Anxiety can be worsened through the use of benzodiazepines.[4]
- Benzodiazepines can lead to a lessening of anxiety symptoms.
- Similarly, long-term alcohol use is associated with anxiety disorders
- Prolonged abstinence can result in a disappearance of anxiety symptoms.
- It can take up to two years for anxiety symptoms to return to baseline in about a quarter of people recovering from alcoholism.
- Tobacco smoking has been established as a risk factor for developing anxiety disorders.[5]
- Excessive caffeine use has been linked to anxiety.
Case Studies
- In 1988–90, illness in approximately half of the patients attending mental health services at British hospital psychiatric clinic, for conditions including anxiety disorders such as panic disorder or social phobia, was determined to be the result of alcohol or benzodiazepine dependence.[6]
- In these patients, anxiety symptoms, while worsening initially during the withdrawal phase, disappeared with abstinence from benzodiazepines or alcohol.
- Sometimes anxiety, pre-existed alcohol, or benzodiazepine dependence, keep anxiety disorders going and often progressively making them worse.
- Recovery from benzodiazepines tends to take a lot longer than recovery from alcohol, but people can regain their previous good health.[7]
References
- ↑ Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
- ↑ Hettema JM, Neale MC, Kendler KS (2001). “A review and meta-analysis of the genetic epidemiology of anxiety disorders”. Am J Psychiatry. 158 (10): 1568–78. doi:10.1176/appi.ajp.158.10.1568. PMID 11578982. Review in: Evid Based Ment Health. 2002 Aug;5(3):92
- ↑ Donner J, Pirkola S, Silander K, Kananen L, Terwilliger JD, Lönnqvist J; et al. (2008). “An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders”. Biol Psychiatry. 64 (8): 672–80. doi:10.1016/j.biopsych.2008.06.002. PMC 2682432. PMID 18639233.
- ↑ Cohen SI (1995). “Alcohol and benzodiazepines generate anxiety, panic and phobias”. J R Soc Med. 88 (2): 73–7. PMC 1295099. PMID 7769598.
- ↑ Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT (2007). “Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships”. Psychol Bull. 133 (2): 245–72. doi:10.1037/0033-2909.133.2.245. PMID 17338599.
- ↑ Ashton H (2005). “The diagnosis and management of benzodiazepine dependence”. Curr Opin Psychiatry. 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
- ↑ Bruce MS, Lader M (1989). “Caffeine abstention in the management of anxiety disorders”. Psychol Med. 19 (1): 211–4. PMID 2727208.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Irfan Dotani
Overview
In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder. Accumulating evidence indicates that patients with comorbid depression and anxiety tend to have greater illness severity and a lower treatment response than those with either disorder alone. In addition, social function and quality of life are more greatly impaired. Approximately one-quarter of the patients with generalized anxiety disorder, will develop panic disorder.
Natural History, Complications and Prognosis
- In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%, and with panic disorder, 9.9%.
- Patients with a diagnosed anxiety disorder also had high rates of comorbid depression, including 22.4% of patients with social phobia, 9.4% with agoraphobia, and 2.3% with panic disorder.[1]
- For many, the symptoms of both depression and anxiety are not severe enough (i.e. are subsyndromal) to justify a primary diagnosis of either major depressive disorder (MDD) or an anxiety disorder.
- Patients can also be categorized as having mixed anxiety-depressive disorder, and they are at significantly increased risk of developing full-blown depression or anxiety. Appropriate treatment is necessary to alleviate symptoms and prevent the emergence of more serious disease.[2]
- Accumulating evidence indicates that patients with comorbid depression and anxiety tend to have greater illness severity and a lower treatment response than those with either disorder alone. In addition, social function and quality of life are more greatly impaired.
- In addition to coexisting with depression, research shows that GAD often coexists with substance abuse or other conditions associated with stress, such as irritable bowel syndrome.
- Patients with physical symptoms such as insomnia or headaches should also tell their doctors about their feelings of worry and tension.[3]
- This will help the patient’s health care provider to recognize whether the person is suffering from GAD.
- Approximately one-quarter of the patients with generalized anxiety disorder, will develop panic disorder.[4]
References
- ↑ Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT (2007). “Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships”. Psychol Bull. 133 (2): 245–72. doi:10.1037/0033-2909.133.2.245. PMID 17338599.
- ↑ Kessler RC, Keller MB, Wittchen HU (March 2001). “The epidemiology of generalized anxiety disorder”. Psychiatr. Clin. North Am. 24 (1): 19–39. PMID 11225507.
- ↑ Newman MG, Przeworski A, Fisher AJ, Borkovec TD (2010). “Diagnostic comorbidity in adults with generalized anxiety disorder: impact of comorbidity on psychotherapy outcome and impact of psychotherapy on comorbid diagnoses”. Behav Ther. 41 (1): 59–72. doi:10.1016/j.beth.2008.12.005. PMC 2827339. PMID 20171328.
- ↑ Shalev I, Moffitt TE, Braithwaite AW, Danese A, Fleming NI, Goldman-Mellor S; et al. (2014). “Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder”. Mol Psychiatry. 19 (11): 1163–70. doi:10.1038/mp.2013.183. PMC 4098012. PMID 24419039.
Diagnosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Laboratory Findings | Other Imaging Findings | Other Diagnostic Studies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
